Skip to main content

Table 2 Comparison of methylation of 7 miR CpG islands in 112 GC samples from patients with various clinicopathological characteristics

From: Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo

Clinicopathological features miR-9-1methylation miR-9-3methylation miR-137methylation miR-34bmethylation miR-200bmethylation miR-375methylation miR-210methylation
Positive rate (%) Proportion, Median* [25-75%] Positive rate (%) Proportion, Median[25-75%] Positive rate (%) Proportion, Median[25-75%] Positive rate (%) Proportion, Median[25-75%] Positive rate (%) Proportion, Median[25-75%] Positive rate (%) Proportion, Median[25-75%] Positive rate (%) Proportion, Median[25-75%]
Age ≤60 (n = 49) 46.9 a 21 [14–38] 68.8 35 [31–42] 95.9 34 [16–48] b 62.5 5 [2–16] 92.9 49 [43–55] 54.3 3 [2–14] 65.1 9 [5–27]
  >60 (n = 63) 73.0 33 [18–44] 61.0 36 [30–44] 93.3 47 [29–61] 54.2 10 [3–23] 87.7 48 [40–56] 38.3 3 [2–14] 72.9 10 [5–17]
Sex Male (n = 80) 61.2 31 [14–45] 62.7 35 [30–42] 96.1 40 [24–54] 53.8 7 [3–18] 88.4 48 [40–56] 44.6 3 [2–7] 69.9 9 [5–17]
  Female (n = 32) 62.5 27 [17–36] 68.8 41 [30–43] 90.6 43 [18–54] 69.0 8 [2–26] 93.3 51 [46–55] 46.9 8 [2–19] 69.0 12 [5–22]
Preoperative chemotherapy No (n = 100) 63.0 32 [16–44] 63.2 35 [30–43] 93.8 39 [23–56] 58.9 7 [3–18] 91.0 49 [41–56] 44.7 4 [2–16] 69.6 9 [5–19]
Yes (n = 9) 55.6 21 [12–31] 66.7 37 [31–54] 100 49 [30–53] 44.4 5 [2–16] 71.4 49 [42–76] 44.4 2 [2–4] 57.1 13 [10–24]
Location Cardiac (n = 34) 64.7 37 [21–47] 65.6 43 [35–51] b 90.9 49 [28–61] b 57.6 8 [3–23] 75.0 d 43 [38–52] 31.2 3 [1–8] 64.5 9 [4–17]
  Non-cardiac (n = 78) 60.3 28 [14–42] 64.0 34 [30–42] 96.1 38 [20–52] 58.1 6 [3–18] 97.0 50 [42–56] 51.4 3 [2–16] 71.8 10 [5–21]
Differentiation Well/Mod. (n = 29) 72.4 a 27 [9–44] 69.0 37 [30–50] 86.2 45 [31–53] 44.4 9 [3–16] 84.6 53 [42–58] 40.7 3 [2–4] 73.1 9 [4–17]
  Poor (n = 78) 56.4 31 [19–42] 63.0 35 [30–42] 97.3 38 [22–55] 64.0 6 [3–19] 91.3 48 [40–54] 45.9 3 [2–14] 66.2 10 [5–21]
Vascular embolus No (n = 60) 65.0 26 [14–45] 70.2 35 [31–43] 89.7 d 45 [26–59] 55.0 10 [3–19] c 92.5 50 [42–57] 51.7 3 [2–13] 70.2 9 [5–20]
Yes (n = 49) 59.2 31 [19–39] 55.3 37 [30–43] 100 39 [22–50] 65.9 3 [2–11] 86.0 48 [40–53] 40.0 5 [2–20] 66.7 11 [5–20]
pTNM stage I-II (n = 40) 70.0 30 [14–47] 67.6 37 [33–45] 89.7 d 46 [35–59] 59.0 10 [3–28] c 91.9 49 [41–56] 51.3 3 [2–8] 64.1 9 [5–19]
  III-IV (n = 59) 59.3 30 [19–40] 60.3 39 [32–43] 100 40 [22–53] 58.2 4 [2–17] 87.8 49 [41–54] 41.8 5 [2–20] 70.0 12 [5–28]
Depth of invasion T1-2 (n = 25) 68.0 34 [11–52] 72.7 36 [31–44] 84.0 e 48 [36–59] 73.9 10 [3–21] 86.4 52 [44–56] 47.8 2 [2–4] 70.8 9 [3–19]
T3 (n = 53) 62.3 28 [17–41] 58.5 35 [30–43] 96.1 43 [28–53] 49.0 7 [2–24] 91.3 46 [36–56] 48.0 5 [2–18] 68.8 10 [5–18]
T4 (n = 25) 60.0 30 [16–38] 62.5 42 [33–44] 100 31 [15–53] 66.7 5 [2–17] 90.9 49 [41–55] 36.0 8 [3–20] 66.7 14 [5–32]
Lymph node metastasis N0 (n = 57) 68.4 26 [13–47] 67.3 35 [32–43] 89.1 d 45 [22–58] 61.8 10 [3–20] 90.6 53 [43–57] c 46.4 2 [2–10] 67.3 9 [5–19]
N1-3 (n = 51) 56.9 31 [21–41] 58.3 39 [30–44] 100 39 [26–52] 58.3 4 [2–16] 88.1 45 [37–52] 47.8 5 [2–20] 69.8 11 [5–23]
Distant metastasis M0 (n = 77) 67.5 a 30 [14–44] 64.4 37 [32–43] 92.0 42 [24–56] 60.0 8 [3–19] 91.5 49 [41–56] 46.7 3 [2–13] 68.1 9 [5–17] c
M1 (n = 31) 51.6 30 [21–40] 60.0 36 [30–43] 100 43 [24–53] 60.7 6 [2–17] 83.3 49 [40–53] 48.1 6 [3–20] 69.2 15 [9–28]
  1. * %; [25-75%], 25%-75% percentiles; a, Pearson’s Chi-square test, miR-9-1 for age, differentiation, distant metastasis: χ 2 = 7.924, 2.271, 2.402, and P = 0.005, 0.132, 0.121, respectively; b, Student t-test: miR-9-3 for location [42 ± 2 (Mean ± SD) vs 34 ± 1], t = 3.303, P = 0.002; miR-137 for age [34 ± 3 vs 44 ± 3], t = −2.651, P = 0.009; for location [46 ± 3 vs 37 ± 2], t = 2.103, P =0.038; c, Mann–Whitney U-test: miR-34b for pTNM stage/ vascular embolus, U = 239.000/320.000, P = 0.028/0.025, miR-200b for lymph node metastasis, U = 627.000, P = 0.021; miR-210 for distant metastasis, U = 301.000, P = 0.048; d, Fisher’s exact test: miR-137 for vascular embolus/pTNM/lymph metastasis, P = 0.031/0.024/0.028; miR-200b for location, P = 0.002; e, Trend test: miR-137 for depth of invasion, χ 2 = 6.330, P = 0.012.